Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECeftobiproleCat.No.:HY-112579CASNo.:209467-52-7Synonyms:Ro63-9141;BAL9141分?式:C??H??N?O?S?分?量:534.57作?靶點(diǎn):Bacterial;Antibiotic作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3years4°C2years*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?。溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:4.95mg/mL(9.26mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.8707mL9.3533mL18.7066mL5mM0.3741mL1.8707mL3.7413mL10mM---------請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?.體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥0.5mg/mL(0.94mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥0.5mg/mL(0.94mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥0.5mg/mL(0.94mM);ClearsolutionBIOLOGICALACTIVITY?物活性Ceftobiprole(Ro63-9141)?種?譜頭孢素，對(duì)甲氧西林(MRSA)、耐萬(wàn)古霉素葡萄球(VRSA)和耐霉素鏈球具有??平的體外活性，對(duì)MRSA的MIC90值為2μg/mL。Ceftobiprole還抑制?蘭?陽(yáng)性和?蘭?性病原體。IC50&Targetβ-lactam體外研究Ceftobiprole(Ro63-9141)hasdemonstratesactivityagainstimportantgram-positivebacteria,includingS.pneumonia(PRSP),Methicillin-resistantS.aureus(MRSA),andE.faecaliswithMIC90valuesof0.25,2,and2mcg/mL,respectively.Ceftobiprolehasalsodemonstratedpotentinvitroactivityagainstseveralclinicalisolatesofcommunity-associatedMethicillin-resistantS.aureus(CA-MRSA),S.aureus(VISA),andS.aureus(VRSA),withaminimuminhibitoryconcentration(MIC)of2mcg/mL[1].CeftobiproleishighlyactiveagainstS.aureus,withMICsrangingfrom0.12to4mg/L(onlyoneresistantstrain,MICof4mg/L).Furthermore,CeftobiproleistwicemoreactiveonMethicillin-susceptibleS.aureus(MSSA)strainswithMIC50andMIC90of0.5mg/LthanonMRSAstrainswithMIC50andMIC90of1mg/L.Moreover,Panton-Valentineleukocidin(PVL)+MRSAareslightlymoresusceptibletoCeftobiprole(MIC50of0.5mg/LandMIC90of1mg/L)thanPVL-MRSA(MIC50andMIC90of1mg/L)[2].戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Antibiotics(Basel).2022,11(10),1351.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].EAzoulay-Dupuis,etal.EfficacyofBAL5788,aprodrugofcephalosporinBAL9141,inamousemodelofacutepneumococcalpneumonia.AntimicrobAgentsChemother.2004Apr;48(4):1105-11.[2].KisgenJ,etal.Ceftobiprole,aBroad-SpectrumCephalosporinWithActivityagainstMethicillin-ResistantStaphylococcusaureus(MRSA).PT.2008Nov;33(11):631-41.[3].HodilleE,etal.Invitroactivityofceftobiproleon440Staphylococcusaureusstrainsisolatedfrombronchopulmonaryinfections.MedMalInfect.2017Mar;47(2):152-157.McePdfHeightCaution:Producthasnotbeenfullyvalidatedform